Dapagliflozin-Associated Hepatotoxicity With a Positive Rechallenge.

Sodium glucose cotransporter 2 inhibitors are generally safe medications, with labelled indications for diabetes mellites, heart failure, and chronic kidney disease. We present a case of suspected dapagliflozin-induced liver injury in a 68-year-old man who presented with 2 weeks of upper abdominal pain, myalgias, and transaminitis following a prior episode of unexplained hepatitis. It was determined that the patient's liver injury with jaundice was likely due to dapagliflozin with a Revised Electronic Causality Assessment Method (RECAM) score of 9 (Highly likely). Laboratory findings and clinical symptoms resolved after discontinuing dapagliflozin during follow up.